Imrecoxib: Advances in Pharmacology and Therapeutics

References

• Mahesh G, Anil Kumar K, Reddanna P. Overview on the discovery and development of anti-inflammatory drugs: should the focus be on synthesis or degradation of PGE2? J Inflamm Res. 2021;14:253–263. doi:10.2147/JIR.S278514
   PubMed Web of Science ®Google Scholar
• Guo ZR. 郭宗儒.国家1类新药艾瑞昔布的研制 [Discovery of imrecoxib]. Chin J New Drugs. 2012;21(3):223–230. Chinese.
   Google Scholar
• Mei Q, Liu Z, Zuo H, Yang Z, Qu J. Idiopathic pulmonary fibrosis: an update on pathogenesis. Front Pharmacol. 2022;12:797292. doi:10.3389/fphar.2021.797292
   PubMedGoogle Scholar
• Miao Y, Yang Y, Li X, et al. Imrecoxib attenuates bleomycin-induced pulmonary fibrosis in mice. Heliyon. 2023;9(11):e20914. doi:10.1016/j.heliyon.2023.e20914
   PubMed Web of Science ®Google Scholar
• Jin H. Imrecoxib inhibits paraquat-induced pulmonary fibrosis through the NF-κB/Snail signaling pathway. Comput Math Methods Med. 2020;2020:6374014. doi:10.1155/2020/6374014
   PubMed Web of Science ®Google Scholar
• Parra ER, Lin F, Martins V, Rangel MP, Capelozzi VL. Immunohistochemical and morphometric evaluation of COX 1 and COX-2 in the remodeled lung in idiopathic pulmonary fibrosis and systemic sclerosis. J Bras Pneumol. 2013;39(6):692–700. doi:10.1590/S1806-37132013000600008
   PubMed Web of Science ®Google Scholar
• Sun Y, Lin Y, Li Q, Li B, Wang D, Huang X. 孙义元,林奕鹏,李棋,等.艾瑞昔布超前镇痛对患者前交叉韧带重建术后镇痛的疗效: 一项随机对照研究 [Effectiveness of preemptive analgesia with imrecoxib on analgesia after anterior cruciate ligament reconstruction: a randomized controlled study]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2023;37(8):982–988. Chinese. doi:10.7507/1002-1892.202304068
   PubMedGoogle Scholar
• Zhang YX, Sun Y, Li XL, Xiao Y, Huang K, Yan LQ. 张亚鑫,孙钰,李小磊,等.艾瑞昔布超前镇痛对全髋关节置换术患者术后早期康复的影响 [Effect of preemptive analgesia with imrecoxib on the early postoperative rehabilitation in patients underwent total Hip arthroplasty]. Jiangsu Med J. 2018;44(11):1247–1249. Chinese. doi:10.19460/j.cnki.0253-3685.2018.11.006
   Google Scholar
• Jia XF, Long M, Huang GP, Ji Y, Zhou Y, Li P. 贾叙锋,龙苗,黄光平,等.艾瑞昔布超前镇痛用于脊柱手术对患者术后镇痛效果的影响 [Effect of preemptive analgesia with imrecoxib on postoperative analgesic effect in patients undergoing spinal surgery]. China Mod Doctor. 2019;57(1):13–19. Chinese.
   Google Scholar
• Zhu YQ, Wang GL, Li SQ, Ding N, Qi Y, Song TY. 朱玉权,王刚林,李栓起,等.腹腔镜胆囊切除术应用艾瑞昔布超前镇痛的效果分析 [Effect of preemptive analgesia with imrecoxib in laparoscopic cholecystectomy]. Clin Misdiagn Misther. 2013;26(8):99–100. Chinese.
   Google Scholar
• Wang GL, Li SQ, Ma PY, Jiang B, Zhang GH, Song TY. 王刚林,李栓起,马朋羽,等.腹腔镜胆道镜联合保胆取石术应用艾瑞昔布超前镇痛的效果分析 [Effect of preemptive analgesia with imrecoxib in laparoscopic choledochoscopy combined with gallbladder-preserving lithotomy]. J Heibei Med Univ. 2013;34(2):225–226. Chinese.
   Google Scholar
• Dembo G, Park SB, Kharasch ED. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology. 2005;102(2):409–415. doi:10.1097/00000542-200502000-00026
   PubMed Web of Science ®Google Scholar
• Zhang K, Miao X, Jiang L, Cui S, Liu Z, Wang Z. Postoperative analgesic efficacy and safety of imrecoxib versus celecoxib in Hip osteoarthritis patients undergoing total Hip arthroplasty: a multi-center, randomized, controlled, non-inferiority study. Inflammopharmacology. 2023;31(4):1813–1822. doi:10.1007/s10787-023-01260-7
   PubMed Web of Science ®Google Scholar
• Guo W, Liu Y, Li J. Imrecoxib versus celecoxib as postoperative analgesia for patients receiving arthroscopic knee surgery: a randomized, controlled, non-inferiority study. Inflammopharmacology. 2022;30(3):875–881. doi:10.1007/s10787-022-00938-8
   PubMed Web of Science ®Google Scholar
• Jiang Y, Qi L, Liu J, et al. Analgesic efficacy of imrecoxib for postoperative pain following oral surgery: a prospective randomized, active-controlled, non-inferiority trial. Ann Transl Med. 2021;9(6):469. doi:10.21037/atm-21-264
   PubMed Web of Science ®Google Scholar
• Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase-2 in cancer: a review. J Cell Physiol. 2019;234(5):5683–5699. doi:10.1002/jcp.27411
   PubMed Web of Science ®Google Scholar
• Wang LC, Cui LJ, Wang DC, Zhao YX, Zhao ZF, Chen G. 王玲婵,崔立静,王东昌,等.艾瑞昔布抑制肺腺癌A549细胞裸鼠移植瘤侵袭和转移及其机制 [Inhibition of invasion and metastasis by imrecoxib and its mechanisms in lung adenocarcinoma A549 cell xenograft in nude mice]. China Oncology. 2017;27(1):1–6. Chinese. doi:10.19401/j.cnki.1007-3639.2017.01.001
   Google Scholar
• Wang DC, Wang LC, Wang LJ, et al. 王东昌,王玲婵,王玲娇,等. 艾瑞昔布联合洛铂对人肺癌裸鼠移植瘤生长及淋巴结转移的抑制作用 [Inhibitory effect of imrecoxib combined with lobaplatin on tumor growth and lymph node metastasis of human lung cancer xenografts in nude mice]. Zhonghua zhong liu za zhi. 2016;38:340–345. Chinese. doi:10.3760/cma.j.issn.0253-3766.2016.05.004
   PubMedGoogle Scholar
• Fournier DB, Gordon GB. COX-2 and colon cancer: potential targets for chemoprevention. J Cell Biochem Suppl. 2000;34:97–102.
   PubMedGoogle Scholar
• Wang XB, Zhou LY, Zhou SP. 王小波,周璐瑶,周少朋.艾瑞昔布联合奥沙利铂对裸鼠人结肠癌LOVO细胞移植瘤模型的细胞凋亡作用机制研究 [Effect and mechanism of imrecoxib combined with oxaliplatin on apoptosis of human colon cancer LOVO cells transplanted in nude mice model]. Chin J Clin Pharmacol. 2020;36(16):2444–2447. Chinese. doi:10.13699/j.cnki.1001-6821.2020.16.018
   Google Scholar
• Lu JM, Lan HS, Wei W, Huang XS, Huang HG. 陆佳明,兰海生,韦维,等.艾瑞昔布联合奥沙利铂对裸鼠结肠癌移植瘤血管形成的影响 [Effects of imrecoxib combined with oxaliplatin on angiogenesis of colon cancer xenograft in nude mice]. Mod J Integr Trad Chin Western Med. 2020;29(12):1288–1293. Chinese.
   Google Scholar
• Sun HQ, Zhang SF, Wang CW, Han RR. 孙会卿,张淑凤,王长武,等.艾瑞昔布联合5-氟尿嘧啶对裸鼠结肠癌移植瘤侵袭和转移的影响 [Effects of etoricoxib combined with fluorouracil on invasion and metastasis of colon cancer xenografts in nude mice]. Drugs Clinic. 2021;36(3):435–440. Chinese. doi:10.7501/j.issn.1674-5515.2021.03.003
   Google Scholar
• Meyerhardt JA, Shi Q, Fuchs CS, et al. Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer: the CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA. 2021;325(13):1277–1286. doi:10.1001/jama.2021.2454
   PubMed Web of Science ®Google Scholar
• Cecil DL, Gad EA, Corulli LR, Drovetto N, Lubet RA, Disis ML. COX-2 inhibitors decrease expression of PD-L1 in colon tumors and increase the influx of type I tumor-infiltrating lymphocytes. Cancer Prev Res. 2022;15(4):225–231. doi:10.1158/1940-6207.CAPR-21-0227
   PubMed Web of Science ®Google Scholar
• Li BY, Xu XJ, Mou ZF, Wang GD, Dong YF. 李冰言,徐祥均,牟志芳,等.艾瑞昔布对离体培养膝骨关节炎软骨细胞的作用及机制 [Effect and mechanism of irecoxib on cultured chondrocytes of knee osteoarthritis in vitro]. Chin J Clin Pharmacol. 2022;38(15):1800–1804. Chinese. doi:10.13699/j.cnki.1001-6821.2022.15.023
   Google Scholar
• Cheleschi S, Veronese N, Carta S, et al. MicroRNA as possible mediators of the synergistic effect of celecoxib and glucosamine sulfate in human osteoarthritic chondrocyte exposed to IL-1β. Int J Mol Sci. 2023;24(19):14994. doi:10.3390/ijms241914994
   PubMed Web of Science ®Google Scholar
• Liao X, Huang L, Yu Q, et al. SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome. Cancer Chemother Pharmacol. 2020;85(4):785–792. doi:10.1007/s00280-020-04053-9
   PubMed Web of Science ®Google Scholar
• Macedo LT, Lima JP, Dos Santos LV, Sasse AD. Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer. 2014;22(6):1585–1593. doi:10.1007/s00520-014-2129-z
   PubMed Web of Science ®Google Scholar
• Liang F. 梁发.艾瑞昔布防治卡培他滨相关性手足综合征临床观察 [Clinical observation on the prevention and treatment of capecitabine-associated hand and foot syndrome with imrecoxib]. J Mod Med Health. 2016;32(17):2708–2709. Chinese. doi:10.3969/j.issn.1009-5519.2016.17.033
   Google Scholar
• Gao GM, Li YM, Zheng XL, et al. The efficacy of imrecoxib and celecoxib in axial spondyloarthritis and their influence on serum dickopff-related protein 1 (DKK-1) levels. Med Sci Monit. 2017;23:2985–2992. doi:10.12659/msm.901727
   PubMed Web of Science ®Google Scholar
• Guo Y, Jiang D, Mai Z, Chen Y, Li T, Gao G. Imrecoxib and celecoxib affect sacroiliac joint inflammation in axSpA by regulating bone metabolism and angiogenesis. Clin Rheumatol. 2023;42(6):1585–1592. doi:10.1007/s10067-023-06541-8
   PubMed Web of Science ®Google Scholar
• Zong HX, Xu SQ, Wang JX, et al. A real-world study on the effect of imrecoxib for patients with axial spondyloarthritis. Drug Des Devel Ther. 2022;16:2755–2765. doi:10.2147/DDDT.S376406
   PubMed Web of Science ®Google Scholar
• Sun X, Zhen X, Hu X, et al. Cost-utility analysis of imrecoxib compared with celecoxib for patients with osteoarthritis. Ann Transl Med. 2021;9(7):575. doi:10.21037/atm-21-290
   PubMed Web of Science ®Google Scholar
• Sun X, Zhen X, Hu X, et al. Cost-utility analysis of imrecoxib compared with diclofenac for patients with osteoarthritis. Cost Eff Resour Alloc. 2021;19(1):22. doi:10.1186/s12962-021-00275-7
   PubMed Web of Science ®Google Scholar
• Meng Q, Zhang Z, Li F, et al. The prescription patterns and safety profiles of oral non-steroidal anti-inflammatory drugs in China: an 8-year real-life analysis. Ann Palliat Med. 2021;10(2):2224–2237. doi:10.21037/apm-20-2356
   PubMed Web of Science ®Google Scholar
• Xie H, Zhang Y, Zhu Z, Wei J, Ainiwaer G, Ge W. Plasma proteomic analysis based on 4D-DIA evaluates the clinical response to imrecoxib in the early treatment of osteoarthritis. Rheumatol Ther. 2024;11(2):269–283. doi:10.1007/s40744-023-00636-z
   PubMed Web of Science ®Google Scholar
• Wu MR, Xie H, Yang N, et al. 吴明如,谢菡,杨娜,等.膝骨关节炎患者口服艾瑞昔布后主要活性成分稳态血药谷浓度监测 [Determination of plasma concentrations of imrecoxib and its two active metabolites in patients with knee osteoarthritis by liquid chromatography tandem mass spectrometry]. Pharm Clin Res. 2023;31(1):11–16. Chinese. doi:10.13664/j.cnki.pcr.2023.01.005
   Google Scholar
• Liu Y, Zhang R, Li Z, et al. Lack of effect of Imrecoxib, an innovative and moderate COX-2 inhibitor, on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. Sci Rep. 2019;9(1):15774. doi:10.1038/s41598-019-51755-z
   PubMedGoogle Scholar
• Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med. 2005;165(2):189–192. doi:10.1001/archinte.165.2.189
   PubMedGoogle Scholar
• Schwartz JI, Agrawal NG, Hartford AH, et al. The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin. J Clin Pharmacol. 2007;47(5):620–627. doi:10.1177/0091270007299758
   PubMed Web of Science ®Google Scholar
• Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003;74(2):130–137. doi:10.1016/S0009-9236(03)00120-6
   PubMed Web of Science ®Google Scholar
• Zuo CZ, Gong Y, Hou XY, et al. Effect of fluconazole on the pharmacokinetic properties of imrecoxib, a novel NSAID: a single-center, open-label, self-controlled Study in healthy Chinese male volunteers. Clin Ther. 2018;40(8):1347–1356. doi:10.1016/j.clinthera.2018.06.009
   PubMed Web of Science ®Google Scholar
• RxList [homepage on the Internet]. CELEBREX; 2022. Available from: https://www.rxlist.com/celebrex-drug.htm#clinpharm. Accessed February 9, 2023.
   Google Scholar
• Ribeiro H, Rodrigues I, Napoleão L, et al. Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: adjusting prescription to patient features. Biomed Pharmacother. 2022;150:112958. doi:10.1016/j.biopha.2022.112958
   PubMed Web of Science ®Google Scholar
• Antman EM, Bennett JS, Daugherty A, et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115(12):1634–1642. doi:10.1161/CIRCULATIONAHA.106.181424
   PubMed Web of Science ®Google Scholar
• Walker C, Biasucci LM. Cardiovascular safety of non-steroidal anti-inflammatory drugs revisited. Postgrad Med. 2018;130(1):55–71. doi:10.1080/00325481.2018.1412799
   PubMed Web of Science ®Google Scholar
• Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther. 2001;296(2):558–566. PMID: 11160644.
   PubMed Web of Science ®Google Scholar
• Chen XH, Bai JY, Shen F, Bai AP, Guo ZR, Cheng GF. Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect. Acta Pharmacol Sin. 2004;25(7):927–931. PMID: 15210067.
   PubMed Web of Science ®Google Scholar
• Luo W, Srinivasulu C, Hao X, Liu X, Zhan P. The increasing impact of Chinese innovative drug research on the global stage with a focus on drug discovery. Expert Opin Drug Discov. 2020;15(10):1115–1120. doi:10.1080/17460441.2020.1775577
   PubMed Web of Science ®Google Scholar
• Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–2529. doi:10.1056/NEJMoa1611593
   PubMed Web of Science ®Google Scholar
• McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296(13):1633–1644. doi:10.1001/jama.296.13.jrv60011
   PubMed Web of Science ®Google Scholar
• Walter MF, Jacob RF, Day CA, Dahlborg R, Weng Y, Mason RP. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis. 2004;17(2):235–243. doi:10.1016/j.atherosclerosis.2004.10.001
   Google Scholar
• Rodrigues AD. Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005;33(11):1567–1575. doi:10.1124/dmd.105.006452
   PubMed Web of Science ®Google Scholar
• Theken KN, Lee CR, Gong L, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther. 2020;108(2):191–200. doi:10.1002/cpt.1830
   PubMed Web of Science ®Google Scholar
• Li Q, Huang HH, Dong Y, Zhong DF. 李强,黄海华,董宇,等.采用重组人源CYP酶研究艾瑞昔布的体外羟基化代谢 [Investigation on the hydroxylation metabolism of imrecoxib in vitro by using recombinant human CYPs]. Yao Xue Xue Bao. 2005;40(10):912–915. doi:10.16438/j.0513-4870.2005.10.010
   PubMedGoogle Scholar
• Lee SJ, Park MK, Shin DS, Chun MH. Variability of the drug response to nonsteroidal anti-inflammatory drugs according to cyclooxygenase-2 genetic polymorphism. Drug Des Devel Ther. 2017;11:2727–2736. doi:10.2147/DDDT.S143807
   PubMed Web of Science ®Google Scholar
• Prasher P, Sharma M, Gunupuru R. Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy. Drug Dev Res. 2021;82(4):469–473. doi:10.1002/ddr.21794
   PubMed Web of Science ®Google Scholar
• Ghaznavi H, Mohammadghasemipour Z, Shirvaliloo M, et al. Short-term celecoxib (celebrex) adjuvant therapy: a clinical trial study on COVID-19 patients. Inflammopharmacology. 2022;30(5):1645–1657. doi:10.1007/s10787-022-01029-4
   PubMed Web of Science ®Google Scholar
• Hong W, Chen Y, You K, et al. Celebrex adjuvant therapy on coronavirus disease 2019: an experimental study. Front Pharmacol. 2020;11:561674. doi:10.3389/fphar.2020.561674
   PubMed Web of Science ®Google Scholar
• Ong SWX, Tan WYT, Chan YH, et al. Safety and potential efficacy of cyclooxygenase-2 inhibitors in coronavirus disease 2019. Clin Transl Immunology. 2020;9(7):e1159. doi:10.1002/cti2.1159
   PubMed Web of Science ®Google Scholar
• By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052–2081. doi:10.1111/jgs.18372
   PubMed Web of Science ®Google Scholar
• Yang L, Shen Q, Hu C, et al. Comparative pharmacokinetics and safety of imrecoxib, a novel selective cyclooxygenase-2 inhibitor, in elderly healthy subjects. Drug Des Devel Ther. 2022;16:3865–3876. doi:10.2147/DDDT.S387508
   PubMed Web of Science ®Google Scholar
• Pei Q, Xie JL, Huang J, et al. Pharmacokinetic study of imrecoxib in patients with renal insufficiency. Eur J Clin Pharmacol. 2019;75(10):1355–1360. doi:10.1007/s00228-019-02698-x
   PubMed Web of Science ®Google Scholar
• Tamaddon M, Gilja H, Wang L, et al. Osteochondral scaffolds for early treatment of cartilage defects in osteoarthritic joints: from bench to clinic. Biomater Transl. 2020;1(1):3–17. doi:10.3877/cma.j.issn.2096-112X.2020.01.002
   PubMedGoogle Scholar
• Wang Y, Chen Y, Wei Y. Osteoarthritis animal models for biomaterial-assisted osteochondral regeneration. Biomater Transl. 2022;3(4):264–279. doi:10.12336/biomatertransl.2022.04.006
   PubMedGoogle Scholar
• Fang C, Guo JW, Wang YJ, et al. Diterbutyl phthalate attenuates osteoarthritis in ACLT mice via suppressing ERK/c-fos/NFATc1 pathway, and subsequently inhibiting subchondral osteoclast fusion. Acta Pharmacol Sin. 2022;43(5):1299–1310. doi:10.1038/s41401-021-00747-9
   PubMed Web of Science ®Google Scholar
• Chang LH, Chen CH, Wu SC, Chang JK, Ho ML. Cyclooxygenase-2 regulates PTHrP transcription in human articular chondrocytes and is involved in the pathophysiology of osteoarthritis in rats. J Orthop Translat. 2021;30:16–30. doi:10.1016/j.jot.2021.06.003
   PubMed Web of Science ®Google Scholar
• Yajun W, Jin C, Zhengrong G, et al. Betaine attenuates osteoarthritis by inhibiting osteoclastogenesis and angiogenesis in subchondral bone. Front Pharmacol. 2021;12:723988. doi:10.3389/fphar.2021.723988
   PubMed Web of Science ®Google Scholar
• Yabas M, Orhan C, Er B, et al. A next generation formulation of curcumin ameliorates experimentally induced osteoarthritis in rats via regulation of inflammatory mediators. Front Immunol. 2021;12:609629. doi:10.3389/fimmu.2021.609629
   PubMed Web of Science ®Google Scholar
• Gallelli L, Galasso O, Falcone D, et al. The effects of nonsteroidal anti-inflammatory drugs on clinical outcomes, synovial fluid cytokine concentration and signal transduction pathways in knee osteoarthritis. A randomized open label trial. Osteoarthritis Cartilage. 2013;21(9):1400–1408. doi:10.1016/j.joca.2013.06.026
   PubMed Web of Science ®Google Scholar
• Bai XJ, He YY, Wang Z, et al. 柏小金,何颖异,王知,等.关节镜清理术联合艾瑞昔布对膝骨性关节炎的疗效及对MMP-2、MMP-13水平的影响 [Effects of arthroscopic debridement combined with imrecoxib on levels of MMP-2 and MMP-13 for knee osteoarthritis]. China J Mod Med. 2018;28(33):107–111. Chinese.
   Google Scholar
• Zeng ZL, Xie H. Mesenchymal stem cell-derived extracellular vesicles: a possible therapeutic strategy for orthopaedic diseases: a narrative review. Biomater Transl. 2022;3(3):175–187. doi:10.12336/biomatertransl.2022.03.002
   PubMedGoogle Scholar
• Liang M, Wang K, Wei X, et al. Replenishing decoy extracellular vesicles inhibits phenotype remodeling of tissue-resident cells in inflammation-driven arthritis. Cell Rep Med. 2023;4(10):101228. doi:10.1016/j.xcrm.2023.101228
   PubMedGoogle Scholar
• Xu C, Zhai Z, Ying H, Lu L, Zhang J, Zeng Y. Curcumin primed ADMSCs derived small extracellular vesicle exert enhanced protective effects on osteoarthritis by inhibiting oxidative stress and chondrocyte apoptosis. J Nanobiotechnol. 2022;20(1):123. doi:10.1186/s12951-022-01339-3
   PubMed Web of Science ®Google Scholar